Clinical trials: Prostatic Disease
Prostate Cancer
Training for Men Undergoing Androgen Deprivation Therapy.
The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).
- Trial name
- ADT-train (NCT06449664)
- Testing
- ADT-train
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- The Swedish School of Sport and Health Sciences
Prostatic Neoplasm
Carboplatin in Castration-resistant Prostate Cancer
Open label, non-randomised phase II clinical pilot study
- Trial name
- PRO-PLAT (NCT02311764)
- Testing
- Carboplatin
- Where
- 3 sites in Switzerland
- Volunteers
- 16 people
- Sponsor
- Aurelius Omlin
Benign Prostatic Hyperplasia
Effect of 50 and 100 IU Doses of Botox A Toxin Injection in BPH Patients.
The primary objective of this study is to compare the efficacy and safety of a single injection of 50 U and 100 U doses of BoNT-A for the treatment of BPH-associated LUTS.
- Trial name
- NCT02524236
- Testing
- Botox injection in the prostate
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Beni-Suef University
Prostate Cancer
Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Stereotactic rt
Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time and by (ii) enabling a safe delivery…
- Trial name
- HypoF-SBRT (NCT06330909)
- Testing
- Radiotherapy (RT) Arm A - IMRT/IGRT/SBRT, Radiotherapy (RT) Arm B - IMRT/IGRT
- Where
- Germany
- Volunteers
- 374 people
- Sponsor
- University Hospital Freiburg
Prostate Cancer
Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance
A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer
- Trial name
- NCT01191099
- Testing
- Pimonidazol
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Prostate Cancer
Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Docetaxel-based therapy has been shown to prolong survival as first-line therapy for patients with hormone refractory prostate cancer (HRPC), and has become the standard of care.
- Trial name
- NCT00216099
- Testing
- Pemetrexed, Folic Acid, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Christopher Sweeney, MBBS
Cancer Of Prostate
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Background: Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment.
- Trial name
- NCT05361798
- Testing
- PDS01ADC, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
BPH, Benign Prostatic Hyperplasia
Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study
This study aims to explore the feasibility of moxibustion as a supplementary intervention and to assess the sample size for verifying the effectiveness and safety of integrative treatment involving moxibustion compared with…
- Conditions
- BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Lower Urinary Tract Symptom
- Trial name
- NCT02051036
- Testing
- Moxibustion
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- JUNGNAM KWON
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Solid Tumor, Breast Cancer
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
The purpose of this study is to determine the safety profile, including the maximum tolerated dose (MTD), of ATI-1123 a liposomal formulation of docetaxel, in the treatment of cancer patients with advanced solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT01041235
- Testing
- ATI-1123 (active drug = docetaxel)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Azaya Therapeutics, Inc.
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
ProsTIC Registry of Men Treated With PSMA Theranostics
This is a descriptive, observational, prospective, open-ended, registry utilising electronic data capture to collect information on the outcomes of men treated with prostate specific-membrane antigen (PSMA) theranostics.
- Trial name
- NCT04769817
- Testing
- 177Lu-PSMA
- Where
- Australia
- Volunteers
- 500 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostatic Hyperplasia
SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
Primary Objective: To assess the sexual function improvement from baseline to the end of treatment (Week 24 or premature withdrawal (PW)) with XATRAL 10mg OD.
- Trial name
- NCT00486785
- Testing
- Alfuzosin
- Where
- 4 sites in Colombia, Ecuador and 2 more
- Volunteers
- 431 people
- Sponsor
- Sanofi
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
Prostate Cancer, Local Anesthesia
A Prospective Randomized Trial of Two Different Prostate Biopsy Schemes
The main purpose is to compare the detection rate of 20-core versus 12-core prostate biopsy. The secondary objective is to evaluate pain perception using a validated scale to compare the analgesia provided by the two different…
- Conditions
- Prostate Cancer, Local Anesthesia, Prostate-Specific Antigen/Blood, Biopsy/Methods
- Trial name
- NCT02825225
- Testing
- 20 core-biopsy fragments, Base and apex local anesthesia
- Where
- Brazil
- Volunteers
- 750 people
- Sponsor
- University of Nove de Julho
Prostate Cancer
Inter-observer Variability in the Segmentation of Prostate Tumour Lesions Using Multiparametric MRI (VARIOP)
Following the major technological and scientific advances in external radiotherapy in recent decades, thanks to the use of three-dimensional conformal techniques combined with intensity modulation, image-guided radiotherapy has…
- Trial name
- VARIOP (NCT05996289)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Brest
Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Identifying Prostate Brachytherapy Seeds Using MRI
This study will look at the feasibility of using a type of Magnetic Resonance Imaging called Susceptibility Weighted Imaging (SWI) to detect your implanted radioactive seeds.
- Trial name
- NCT01878058
- Testing
- MRI Scan
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer, Prostate Adenocarcinoma
Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection
The aim of this study is to compare clinically significant prostate cancer detection rate by the 4 biopsy methods: TRUS-guided, cognitive, fusion and transperineal template mapping biopsy.
- Trial name
- NCT05589558
- Testing
- consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)
- Where
- Russia
- Volunteers
- 102 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
This is a Phase 1, open-label, multicenter study of continuous oral dosing of AZD4635 administered to patients with advanced solid malignancies.
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Trial name
- NCT02740985
- Testing
- AZD4635, Durvalumab, Abiraterone Acetate
- Where
- 17 sites in United States
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.